Scientific Program

Conference Series Ltd invites all the participants across the globe to attend International Conference on Diabetes and its Complications Osaka, Japan.

Day 1 :

OMICS International  Diabetic Complications 2018 International Conference Keynote Speaker Toshihide Shima photo

Toshihide Shima has completed his MD at the age of 24 years from Kyoto Prefectural University of Medicine. He is the vice president of Suita Hospital of Saiseikai, Imperial Gift Foundation, inc. He has published more than 10 papers on nonalcoholic steatohepatitis (NASH) and has been serving as an international member of American Association for the Study of Liver Diseases (AASLD).



We reported a cross-sectional study on causes of liver injury in Japanese type 2 diabetes mellitus (T2D) patients (J of Gastroenterology 48, 2013). We assessed overall and cause-specific mortality risk during follow-up of patients enrolled in JG 2013.
Methods: Of the 5,642 Japanese T2D patients who visited T2D clinics of nine hospitals in the original study, 3,999 patients were followed up for an average of 4.5 years. Expected deaths in T2D patients were estimated using age-specific mortality rates in the general population (GP) of Japan. Standardized mortality ratios (SMRs) were calculated to compare mortality between T2D patients and GP.
Results: All-cancer mortality was significantly higher in T2D patients than in GP [SMR 1.58, 95% confidence interval (CI) 1.21–2.06], whereas all-cause mortality was comparable between the groups (SMR 1.10, 95% CI 0.93–1.32). Among malignancies, hepatocellular carcinoma (HCC) conferred the highest mortality risk in T2D patients (SMR 3.57, 95% CI 1.66–7.67). HCC-associated mortality risk in T2D patients remained significantly high (SMR 2.56, 95% CI 1.15–5.68) after adjusting for high positivity rates of hepatitis B surface antigen (1.7%) and anti-hepatitis C virus (5.3%). In T2D patients with platelet counts < 200 × 103/μl, SMR of HCC increased from 3.57 to 6.58 (95% CI 2.33–18.60).
Conclusions: HCC-associated mortality risk was the highest among all cancers in Japanese T2D patients. Regular follow-up may be important for T2D patients with platelet counts < 200 × 103/μl for early detection of HCC.

Keynote Forum

Sebastian Oltean

University of Exeter,United Kingdom

Keynote: Alternative Splicing in Diabetic Nephropathy and other Chronic Kidney Diseases

Time : 09:30 - 10:00

OMICS International  Diabetic Complications 2018 International Conference Keynote Speaker Sebastian Oltean photo

Sebastian studied clinical medicine at  “Iuliu Hatieganu” Medical School, Cluj-Napoca, Romania and trained as a junior doctor in Nephrology and Dialysis before moving to USA where he obtained a PhD from the University of Nebraska-Lincoln in 2004.This was followed by postdoctoral training at Duke University Medical Center (North Carolina, USA) where he became interested in studying the connections between alternative splicing and cancer. In 2008 he moved to the University of Bristol where he continued to study alternative splicing in vivo, with focus towards the importance of several genes splice isoforms (e.g VEGF, FGFR2) in cancer as well as kidney diseases and development of splice-based therapeutics. In 2012 he was appointed independent research fellow and principal investigator and developed his own research group in Bristol before moving to University of Exeter Medical School in 2017, where he is now a Senior Lecturer.



Alternative splicing (AS) has emerged in the post-genomic era as one of the main drivers of proteome diversity with at least 94% of multi-exon genes being alternatively spliced in humans. AS is therefore one of the main control mechanisms for cell phenotype, and a process deregulated in disease. Numerous reports describe pathogenic mutations in splice factors, splice sites or regulatory sequences; additionally, in many cases there is an abnormal proportion of splice isoforms (or novel isoforms) in disease compared to the physiological pattern, without an apparent driver mutation. It has therefore become essential to study how AS is regulated in physiology, how it contributes to pathogenesis and whether we can manipulate faulty splicing for therapeutic advantage. While the disease most commonly linked to deregulation of AS in several genes is cancer, there are many in-depth reports of pathogenic splice variants in diseases ranging from neuromuscular disorders to diabetes or cardiomyopathies. In recent years, a plethora of splice variants have been implicated in chronic kidney diseases as well. Examples of these and ideas on how to manipulate them for therapeutic benefit will be presented in this talk.

Keynote Forum

Megan Stevens

University of Exeter, United Kingdom

Keynote: The natural drug DIAVIT is protective in a type II mouse model of diabetic nephropathy

Time : 10:00 - 10:30

OMICS International  Diabetic Complications 2018 International Conference Keynote Speaker Megan Stevens photo

I am currently working as a Research Fellow at the University of Exeter, UK as part of Dr Sebastian Oltean’s group. I have a background in the alternative splicing of VEGF-A as a therapeutic in chronic kidney disease. I am currently focused on exploring alternative splicing events in diabetic nephropathy, and how DIAVIT and other small molecules can be used to modulate splicing in a therapeutic manner.


Statement of the Problem: There is evidence to suggest that abnormal angiogenesis, inflammation, and fibrosis drive diabetic nephropathy (DN). However, there is no specific treatment to counteract these processes. We aimed to determine whether DIAVIT, a natural Vaccinium myrtillus (blueberry) and Hippophae Rhamnoides (sea buckthorn) extract, is protective in a model of type II DN. Methodology & Theoretical Orientation: Diabetic db/db mice were administered DIAVIT in their drinking water for 14 weeks. We assessed the functional, structural, and ultra-structural phenotype of three experimental groups (lean+vehicle, db/db+vehicle, db/db+DIAVIT), and the angiogenic and fibrotic pathways involved in the DIAVIT mechanism. Findings: Diabetic db/db mice developed hyperglycemia, albuminuria, and an increased glomerular water permeability; the latter two were prevented by DIAVIT. db/db mice developed fibrotic glomeruli, endothelial insult, and glomerular ultra-structural changes, which were absent in DIAVIT-treated mice. VEGF-A splicing was altered in the db/db kidney cortex, increasing pro-angiogenic VEGF-A165 relative to anti-angiogenic VEGF-A165b. This was partially reversed with DIAVIT. TNFα-induced nuclear translocation of p65-NFĸB in cultured glomerular endothelial cells was also prevented by DIAVIT. Conclusion & Significance: In conclusion, DIAVIT alters VEGF-A splicing and p65-NFĸB activation, rescuing the DN phenotype. This study highlights the therapeutic potential of natural drugs in DN through the manipulation of gene splicing and expression.

Keynote Forum

Adil Omar Bahathiq

Um-Alqura University, Saudi Arabia

Keynote: Metabolic Syndrome in young Saudi female

Time : 11:00 - 11:30

OMICS International  Diabetic Complications 2018 International Conference Keynote Speaker Adil Omar Bahathiq photo

Adil O. Bahathiq had initial experience of the research tools with Professors Ian Cooke and William Ledger at University of Sheffield, U.K. He found new data the Fallopian tube and epididymis for his Ph.D. Then he conducted a new line of research that helped and improved the health of the community. He has developed this area after years of experience in research, evaluation, teaching and administration both in hospital and educational institutions. This research area was chosen because of the lack of data relating to obesity and the metabolic syndrome in the children and adults of the Makkah community. The findings of this research have been beneficial to the authorities in the fields of education and health in Saudi Arabia.



It is ironic that as people continue to suffer from malnourishment and starvation in some poor parts of the world, others have gone to the other extreme of being overweight or obese particularly in developed, but also in developing countries.   The modern world is faced with a terrifying new ‘disease’ that is ‘obesity’. As people get fatter, excess weight is now seen as unhealthy and socially damaging. Obesity can lead to a variety of conditions such as hypertension, hypertriglyceridemia, hypercholesterolemia and high glucose level. These conditions together are called metabolic syndrome.
The syndrome is a cluster of metabolic abnormalities and risk factors that significantly increase the risk of cardiovascular disease and diabetes. It is characterised by a group of metabolic risk factors which include abdominal obesity, atherogenic dyslipidemia, elevated blood pressure and insulin resistance or glucose intolerance. Metabolic syndrome is a state of chronic low-grade inflammation as a consequence of complex interplay between genetic and environmental factors.
The present data were the first to investigate the prevalence of metabolic syndrome among female school children and adolescents in the Makkah area. There were1356 participant’s (6 to 18 years) in this study. Body mass index, waist circumference, blood glucose level, lipid profile, and arterial blood pressure were determined. The Criteria of the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) were used to diagnose metabolic syndrome among participants. Among 1356 female participant, 15.2% were overweight and 15.3% were obese. The prevalence of metabolic syndrome was 17.1% overall, 62% in obese and 50% in overweight participants. An enormous population of Saudi children and adolescents, particularly females, have the potential to develop metabolic syndrome. We recommend a national obesity prevention program at to be implemented at community level to promote leaner and consequently healthier communities; lifestyle modification, and screening for risk factors for metabolic syndrome should be given special consideration.